Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients

Nephrology

Volumn 10, Issue 6, 2005, Pages 583-587

  Labonia, Walter ^a,b   Rubio, Debora ^a   Arias, Carlos ^a  

^a Hospital Santojanni Buenos Aires   (Argentina)

^b República de la India 2945 3A ^*  (Argentina)

Author keywords

Haemodialysis; Inflammation; Iron; Melatonin

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN; MELATONIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; KIDNEY FAILURE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATOCRIT; HEMOGLOBINS; HUMANS; IRON; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MELATONIN; MIDDLE AGED; RENAL DIALYSIS; RETICULOENDOTHELIAL SYSTEM; TRANSFERRIN;

EID: 29144442281     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00488.x     Document Type: Article

References (35)

1. Bergstrom J, Lindholm B, Lacson E et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin. Dial. 2000; 13: 163-75.
2. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol. Dial. Transplant. 2001; 16 (Suppl. 7): 36-40.
3. Kimmel PL, Phillips TL, Simmens SJ et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998; 54: 236-44.
4. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998; 32: 107-14.
5. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639-47.
6. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol. 1999; 10: 610-19.
7. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am. J. Kidney Dis. 1999; 34: 125-34.
8. Rogers J, Durmowitz G, Kasschau K et al. A motif within the 5′ noncoding regions of hepatic acute phase mRNAs mediates ferritin translation by interleukin-1β and may contribute to the anemia of chronic disease. Blood 1991; (Suppl. 1): 367a.
9. Rogers J, Lacroix L, Durmowitz G et al. The role of cytokines in the regulation of ferritin expression. Adv. Exp. Med. Biol. 1994; 356: 127-32.
10. Rogers JT, Andriotakis JL, Lacroix L et al. Translational enhancement of H-ferritin mRNA by interleukin-1β acts through 5′ leader sequences distinct from the iron responsive element. Nucleic. Acids Res. 1994; 22: 2678-86.
11. Feelders RA, Vreugdenhil G, Eggermont AM et al. Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur. J. Clin. Invest. 1998; 28: 520-27.
12. Van Snick JL, Masson PL, Heremans JF. The involvement of lactoferrin in the hyposideremia of acute inflammation. J. Exp. Med. 1974; 140: 1068-84.
13. Rosenlöf K, Kivivuori SM, Grönhagen-Riska C et al. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin. Nephrol. 1995; 43: 249-55.
14. Kaysen GA. Interpretation of plasma protein measurements in end-stage renal disease. Blood Purif. 2000; 18: 337-42.
15. Lissoni P. The pineal gland as a central regulator of cytokine network. Neuroendocrinol. Lett. 1999; 20: 343-9.
16. Sacco S, Aquilini L, Ghezzi P et al. Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro. Eur. J. Pharmacol. 1998; 343: 249-55.
17. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr. Top. Med. Chem. 2002; 2: 167-79.
18. Herrera J, Nava M, Romero F et al. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am. J. Kidney Dis. 2001; 37: 750-57.
19. Memoli B, Postiglione L, Cianciaruso B et al. Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int. 2000; 58: 417-24.
20. Kaysen GA, Kumar V. Inflammation in ESRD: Causes and potential consequences. J. Ren. Nutr. 2003; 13: 158-60.
21. Dalle-Donne I, Giustarini D, Colombo R et al. Protein carbonylation in human diseases. Trends Mol. Med. 2003; 9: 169-76.
22. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol. Dial. Transplant. 2002; 17 (Suppl. 11): 39-43.
23. Means RT, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J. Cell Physiol. 1992; 150: 59-64.
24. Allen DA, Breen C, Yaqoob MM et al. Inhibition of CFU-E formation in uremic patients with inflammatory disease: Role of IFN-gamma and TNF-alpha. J. Invest. Med. 1999; 47: 204-11.
25. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-94.
26. Goicoechea M, Martin J, de Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54: 1337-43.
27. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int. 1999; 55 (Suppl. 69): S107-18.
28. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol. Dial. Transplant. 1999; 14: 2680-87.
29. Hörl WH. Adjunctive therapy in anaemia management. Nephrol. Dial. Transplant. 2002; 17 (Suppl. 5): 56-9.
30. Tarng DC, Wei YH, Huang TP et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999; 55: 2477-86.
31. Gastaldello K, Vereerstraeten A, Nzame-Nze T et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol. Dial. Transplant. 1995; 10 (Suppl. 6): 44-7.
32. Chen WT, Lin YF, Yu FC et al. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: Influence of serum ferritin levels. Am. J. Kidney Dis. 2003; 42: 158-66.
33. Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann. NY Acad. Sci. 1994; 741: 1-38.
34. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 1997; 336: 186-95.
35. Lissoni P, Paolorossi F, Tancini G et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur. J. Cancer 1996; 32A: 1340-43.